Entera Bio (ENTX) Stock Analysis: AI Score & Alternative Data
ENTX alt-data: web traffic climbing, sentiment lagging
Is Entera Bio a buy right now? The alternative data says hold. This ENTX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Entera Bio every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 45/100: a Hold. The stock trades at $2.66 with a $462M market cap.
The bullish side of the 90-day ledger: web traffic up 28.7% to 4K monthly visits, and headcount (according to LinkedIn) up 14.3% to 24 employees. The drag: sentiment down 19.0% to 81/100. That tension is what keeps the score mid-range.
ENTX’s broader alt-data profile also covers X followers (84). Every signal links to its own page with full history, the ENTX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ENTX is just below.
Entera Bio AI Stock Analysis
Entera Bio is a biotechnology company focused on the development and commercialization of orally delivered large molecule therapeutics. The company is leveraging its proprietary oral drug delivery platform to transform the way biologics are administered, with the goal of improving patient compliance and outcomes.
Analysis generated October 2, 2026.
Recent Entera Bio Stock Alerts
|
Entera Bio | October 9 Price is up by 6.4% in the last 24h. |
|
Entera Bio | October 5 Price is down by -6.3% in the last 24h. |
|
Entera Bio | September 30 Price is up by 6.1% in the last 24h. |
|
Entera Bio | September 23 Price is down by -6% in the last 24h. |
Entera Bio Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 28.7% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 24 | 14.3% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 81 | 19.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 14 | 1,300.0% | |
| Stocktwits Mentions | 5 | 66.7% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 7K | 0.9% | |
| X Followers | 84 | 10.5% | |
| Instagram Followers | 31 | 3.1% | |
| Facebook Followers | 31 | 10.7% | |
| Facebook Engagement | 8 | 700.0% |
About Entera Bio (ENTX)
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
| Price | $2.66 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $462M |
| Year Range | $1 – $4 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Entera Bio News
View more → |
Entera Bio shares slip as Q2 loss comes in wider than expectedAugust 10 - Biztoc.com |
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceJuly 31 - GlobeNewswire |
|
 |
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEJuly 29 - PRNewswire |
Entera Bio Announces Pricing of Oversubscribed $275 Million Private PlacementJuly 27 - GlobeNewswire |
|
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with OsteoporosisJune 22 - GlobeNewswire |
See Entera Bio’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ENTX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEEntera Bio Earnings & Financial Performance
View all earnings →Entera Bio Insider Trading Activity
View all →| No recent insider transactions on file. |
Entera Bio Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Entera Bio
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Capricor TherapeuticsCAPR |
$7.83 2.3% | $455M | 49 |
 |
ProthenaPRTA |
$8.84 2.7% | $454M | 47 |
 |
DiaMedica TherapeuticsDMAC |
$8.33 4.0% | $449M | 53 |
 |
YD BioYDES |
$6.73 16.2% | $477M | 56 |
 |
Editas MedicineEDIT |
$2.90 2.1% | $445M | 59 |
Explore Entera Bio Data
Frequently Asked Questions: Entera Bio (ENTX)
Entera Bio has an AltIndex AI Score of 45/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
45/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Entera Bio (ENTX) stock is $2.66 with a market cap of $462M.
As of today, Entera Bio’s PE (Price to Earnings) ratio is —.
View the latest Entera Bio insider transactions to see recent buying and selling activity by company executives and directors.
Check the Entera Bio congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ENTX stock price chart above shows Entera Bio’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Entera Bio technical analysis for RSI, moving averages, and more.
See the stocks similar to Entera Bio section on this page for companies in the same industry ranked by market cap and AI Score.
